Johnson and Johnson Spravato Sales Growth Validates Commercial Potential for Psychedelic Drug Developers

The robust second quarter sales performance of Johnson and Johnson’s Spravato depression treatment has reinforced investment bank Jefferies’ view that psychedelic drug developers may be addressing a commercially viable market opportunity. The data provides a positive indication for companies including Atai Life Sciences, Compass Pathways and Cybin, all of which are advancing clinical programmes in mental health disorders.

Johnson and Johnson reported worldwide second quarter Spravato sales of 584 million dollars, representing a 25 per cent increase from the first quarter. United States sales accounted for 514 million dollars of the total. Jefferies analysts noted that these figures suggest an annualised revenue run rate exceeding 2.3 billion dollars, keeping the product on course to achieve the company’s previously stated annual sales guidance of between 3 billion and 3.5 billion dollars by the 2027 to 2028 period.

Spravato, which is esketamine delivered via nasal spray, has gained traction in treatment resistant depression and major depressive disorder with suicidal ideation. Jefferies stated that the drug’s commercial momentum supports the proposition that psychedelic compounds can achieve market success in challenging mental health conditions. The investment bank attributed this success in part to Johnson and Johnson’s infrastructure investments, including treatment site expansion, physician education initiatives and reimbursement arrangements.

The pharmaceutical giant has guided towards peak annual Spravato sales of up to 5 billion dollars. Jefferies estimated that the therapy may have treated more than 250,000 patients worldwide on a cumulative basis, demonstrating meaningful patient adoption.

The analysts identified several factors contributing to heightened investor interest in psychedelic medicines. These include positive mid stage and late stage clinical trial results across multiple indications such as depression, anxiety and post traumatic stress disorder. Jefferies also pointed to what it characterised as an improving regulatory environment and increasing engagement from major pharmaceutical corporations.

Compass Pathways represents one of the sector’s most advanced programmes, with the company planning to complete a rolling New Drug Application for its COMP360 candidate in the fourth quarter of 2026. This timeline could support a potential regulatory approval by year end and enable a commercial launch during the first half of 2027.

Atai Life Sciences is conducting a Phase III programme for BPL-003 in treatment resistant depression, with data anticipated in early 2029. The company also expects Phase II data for VLS-01 later this year. Jefferies noted that BPL-003, which is delivered intranasally, could potentially utilise the same two hour treatment framework currently employed for Spravato administration.

The investment bank highlighted that Johnson and Johnson has established a network of approximately 7,000 to 8,000 treatment sites across the United States. This infrastructure could facilitate broader adoption of psychedelic therapies as additional products receive regulatory approval and enter commercial distribution.

The Spravato sales trajectory provides tangible evidence of market demand for novel psychiatric treatments and validates the commercial strategy of establishing dedicated treatment centres with trained personnel. This model addresses both the clinical supervision requirements and reimbursement pathways necessary for psychedelic assisted therapies to achieve mainstream medical adoption.